CYPHERPUNK TECHNOLOGIES INC.
CYPHNasdaq
$0.71
↓ -0.6%Jul 17 close · end-of-day
Price
1Y↑ +102.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$119.0M
Enterprise Value
$112.3M
P/E
—
P/S
—
P/B
1.4
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$56.7M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-67.2%
ROIC
-30.5%
Debt / Equity
—
Net Cash
$6.7M
Return 1Y
+107.7%
Company profile
Leap Therapeutics, Inc. acquires and develops therapies for the treatment of cancer. DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers.
- CEO
- Doug E. Onsi
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 40
- Headquarters
- Massachusetts
- Website
- leaptx.com
Management & directors
- Onsi Douglas ECEO,CFO,Pres.,GC,Treas.&Sec.
Roles derived from SEC Form 4 filings.
Earnings
CYPH Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.46↑ +24.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $1.5M | $1.5M | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$28.5M | -$41.4M | -$56.8M | -$87.0M | -$70.1M | -$41.1M |
| Net income | -$27.5M | -$40.6M | -$54.6M | -$81.0M | -$68.0M | $5.0M |
| Diluted EPS | -$0.63 | -$0.47 | -$4.82 | -$3.98 | -$1.81 | $0.07 |
| Operating cash flow | -$26.0M | -$35.2M | -$49.0M | -$43.8M | -$60.3M | -$43.9M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -1902.6% | -2761.7% | — | — | — | — |
| Net margin | -1834.3% | -2705.8% | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$21.3M | -$17.9M | -$16.1M | -$15.9M | -$16.9M | -$3.2M | -$5.1M | -$4.8M |
| Net income | -$20.1M | -$18.2M | -$15.9M | -$15.4M | -$16.6M | -$3.3M | $40.4M | -$77.2M |
| Diluted EPS | -$0.52 | -$0.44 | -$0.34 | -$0.37 | -$0.40 | -$0.08 | $0.92 | -$0.46 |
| Operating cash flow | -$13.7M | -$15.6M | -$15.5M | -$14.5M | -$14.5M | -$8.3M | -$6.6M | -$3.4M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jun 5, 2026
Mar 9, 2026
Dec 31, 2025
Dec 30, 2025
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-03-26 | Mirabelli Christopher | Sale | 60,000 | $0.71 | $42,630.00 | filing |
| 2026-03-13 | Dietz Thomas John | Option exercise | 104,500 | — | — | filing |
| 2026-03-13 | Mirabelli Christopher | Option exercise | 74,700 | — | — | filing |
| 2026-03-13 | Mirabelli Christopher | Option exercise | 94,050 | — | — | filing |
| 2026-03-13 | Oei Khing Djien | Option exercise | 74,700 | — | — | filing |
| 2026-03-13 | Oei Khing Djien | Option exercise | 94,050 | — | — | filing |
| 2026-03-13 | LI WILLIAM | Option exercise | 74,700 | — | — | filing |
| 2026-03-13 | LI WILLIAM | Option exercise | 94,050 | — | — | filing |
| 2026-03-13 | Richard Christian M | Option exercise | 74,700 | — | — | filing |
| 2026-03-13 | Richard Christian M | Option exercise | 94,050 | — | — | filing |
| 2026-03-13 | Mashiach Nissim | Option exercise | 74,700 | — | — | filing |
| 2026-03-13 | Mashiach Nissim | Option exercise | 94,050 | — | — | filing |
| 2026-03-13 | Martin Patricia A. | Option exercise | 74,700 | — | — | filing |
| 2026-03-13 | Schilsky Richard | Option exercise | 74,700 | — | — | filing |
| 2026-03-13 | Schilsky Richard | Option exercise | 94,050 | — | — | filing |
| 2026-03-13 | LOSCALZO JOSEPH | Option exercise | 74,700 | — | — | filing |
| 2026-03-13 | LOSCALZO JOSEPH | Option exercise | 94,050 | — | — | filing |
| 2026-03-13 | CAVANAUGH JAMES H | Option exercise | 74,700 | — | — | filing |
| 2026-03-13 | CAVANAUGH JAMES H | Option exercise | 94,050 | — | — | filing |
| 2026-03-13 | Martin Patricia A. | Option exercise | 94,050 | — | — | filing |
| 2025-12-26 | Dietz Thomas John | Tax withholding | 35,000 | $1.20 | $42,000.00 | filing |
| 2025-12-26 | Dietz Thomas John | Option exercise | 83,000 | — | — | filing |
| 2025-12-23 | Mirabelli Christopher | J | 2,136 | $0.00 | $0.00 | filing |
| 2025-12-23 | Mirabelli Christopher | J | 712 | $0.00 | $0.00 | filing |
| 2025-12-23 | ONSI DOUGLAS E· CEO,CFO,Pres.,GC,Treas.&Sec. | J | 2,136 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.